Transdel Pharmaceuticals Provides Update on Cosmeceutical Product Development

LA JOLLA, Calif., March 30 /PRNewswire-FirstCall/ -- Transdel Pharmaceuticals,
Inc. (OTC Bulletin Board: TDLP, www.transdelpharma.com), a specialty
pharmaceutical company focused on developing and commercializing non-invasive,
topically administered medications, has recently expanded its product
development programs to include cosmetic /cosmeceutical products utilizing the
company's patented Transdel(TM) delivery technology. This new product line
includes an anti-cellulite product, which addresses a very large demand in the
marketplace.

For the Company's anti-cellulite product, the Company now has initial clinical
information supporting the efficacy of this key product. Transdel is
currently in discussions with potential sales and marketing partners for this
product and is targeting to introduce it into the market in 2009. The
Company's potential pipeline of other cosmetic/cosmeceutical products, for
which it is pursuing discussions with potential partners, includes anti-aging,
varicose vein and hyperpigmentation formulations.

"The cosmeceutical products we are developing and testing are exciting
prospects for Transdel," said Dr. Juliet Singh, President and CEO of Transdel.
"A significant market opportunity exists for effective cosmetic and
cosmeceutical products, especially for an anti-cellulite product. Given the
right sales and marketing partner and considering the potentially faster time
to market for such products, we believe that entry into the
cosmetic/cosmeceutical space holds tremendous potential for the Company."

About Transdel Pharmaceuticals, Inc.

Transdel Pharmaceuticals, Inc. (OTCBB: TDLP - News) is a specialty
pharmaceutical company developing non-invasive, topically delivered
medications. The Company's innovative-patented Transdel(TM) cream formulation
technology is designed to facilitate the effective penetration of drugs
through the tough skin barrier to reach the target underlying tissues. In the
case of Ketotransdel(R), the Transdel(TM) cream allows the active ingredient
ketoprofen, a non steroidal anti-inflammatory drug, to reach the target soft
tissue and exert its well-known anti-inflammatory and analgesic effects. The
Company is also investigating other drug candidates and treatments for
transdermal delivery using the Transdel(TM) platform technology for products
in pain management and other therapeutic areas and for cosmetic/cosmeceutical
products. For more information, please visit http://www.transdelpharma.com.

Safe Harbor Statement

Statements made in this release that are not historical in nature constitute
forward-looking statements within the meaning of the Safe Harbor Provisions of
the Private Securities Litigation Reform Act of 1995. Forward-looking
statements can be identified by the use of words such as "expects," "plans,"
"will," "may," "anticipates," "believes," "should," "intends," "estimates,"
and other words of similar meaning. These statements are subject to risks and
uncertainties that cannot be predicted or quantified and consequently, actual
results may differ materially from those expressed or implied by such
forward-looking statements. Such risks and uncertainties include, without
limitation, risks and uncertainties associated with the uncertainty of future
financial results, additional financing requirements, development of new
products, government approval processes, the impact of competitive products or
pricing, and technological changes. More detailed information about the
Company and the risk factors that may affect the realization of
forward-looking statements is set forth in the Company's filings with the
Securities and Exchange Commission, including the Company's Annual Report on
Form 10-K filed with the SEC on March 26, 2009. Such documents may be read
free of charge on the SEC's web site at www.sec.gov. All forward-looking
statements included in this release are made as of the date of this press
release, and the Company assumes no obligation to update any such
forward-looking statements.

SOURCE Transdel Pharmaceuticals, Inc.

John Lomoro, CFO, Transdel Pharmaceuticals, Inc., +1-858-457-5300,
johnl@transdelpharma.com